No Data
Livzon pharma (01513.HK) spent 32.2752 million yuan to repurchase 0.858 million A-shares on November 19.
Gelonghui November 19th | Livzon Pharma (01513.HK) announced that on November 19, 2024, it spent 32.2752 million RMB to repurchase 0.858 million shares of A shares, with a repurchase price of 37.35-37.8 yuan per share.
livzon pharma (01513.HK) spent 32.63 million yuan to repurchase 0.875 million shares of A shares on November 18.
Livzon Pharma (01513.HK) announced on November 18 that it will spend 32.63 million RMB to repurchase 0.875 million shares of A shares on November 18, 2024, at a repurchase price of 37.06-37.58 yuan per share.
Open Source Securities' investment strategy for the pharmaceutical industry in 2025: The long-term industry trend has not changed, focusing on the sector stabilizing and rebounding.
At the current stage, the pharmaceutical policy tends to be stable, the rapidly growing unmet clinical needs under the background of aging, and the continuous improvement of enterprise innovation capabilities are long-term industry trends that have not changed; at the same time, with the macroeconomic improvement, it is expected that the growth rate of medical insurance income suppressing the pharmaceutical sector will gradually improve.
On November 15, livzon pharma (01513.HK) spent 31.685 million yuan to repurchase 0.848 million A-shares.
Gelonghui, November 15丨Livzon Pharma (01513.HK) announced that on November 15, 2024, it spent 31.685 million yuan to repurchase 0.848 million shares of A-shares, with the repurchase price per share ranging from 37.11 to 37.6 yuan.
The new policy of prepayment of medical insurance fund has been released, and the pharmaceutical sector has ushered in a sharp rise. Experts believe it may be a way for medical institutions to release funding pressure.
On the 11th, the "Notice on Prepayment of Medical Insurance Fund" was issued, requiring the unified and improved basic medical insurance fund prepayment system at the national level. Experts believe that the prepayment system can effectively alleviate the problem of pharmaceutical industry debt, accelerate the turnover of funds for pharmaceutical companies. The medical sector showed a significant upward trend today, with listed companies attributing the rise to investor sentiment.
Multiple bullish factors boost pharmaceutical Hong Kong stocks. Institutions say they still face this risk in the short term.
①What are the policy measures to support the field of innovative drugs? ②What unfavorable effects on domestic pharmaceutical stocks might Trump's election bring about?
The Market Doesn't Like What It Sees From Livzon Pharmaceutical Group Inc.'s (SZSE:000513) Earnings YetNo Data
No Data
